Related Experiment Video
Updated: Aug 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Stroke prevention in atrial fibrillation: warfarin faces its challengers
Joseph L Blackshear1, Fred Kusumoto
1Mayo Clinic-Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA. blackshear.joseph@mayo.edu
Abstract:
Warfarin is exceedingly effective and underutilized in treating atrial fibrillation. Recently completed studies of alternative therapies include trials of ximelagatran versus warfarin, antiplatelet therapy plus lower-intensity warfarin versus usual warfarin, and strategies of rhythm versus rate control. Results of these studies suggest new options for treatment, and caveats regarding those who appear to have durable sinus rhythm. Ongoing trials include studies of combined antiplatelet therapy and other antithrombins. Nonpharmacologic approaches include the Maze III procedure and similar operations, left atrial appendage obliteration, and catheter-based radiofrequency ablation procedures. The place of these latter therapies will only be defined through subsequent clinical trials.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
